Pharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique

[en] Osteoarthritis is now considered in all developed countries as a major burden for public health. During several years, the pharmacological management of osteoarthritis mainly focused on symptoms relief without interaction with the long-term structural progression of this disease. Based on recently published consensus, the present article summarizes the currently available options in the symptom-modifying management of osteoarthritis.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Henrotin, Yves ; Université de Liège - ULiège > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Language :

French

Title :

Pharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique

Alternative titles :

[en] Pharmacy Clinics. How I Treat...Arthritis. First Part: Pathophysiologic Recurrence and Symptomatic Treatment

Publication date :

February 2001

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

63-7

Peer reviewed :

Peer reviewed

Available on ORBi :

since 02 May 2012

Statistics

Number of views

124 (4 by ULiège)

Number of downloads

119 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

.
(1999) Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis, FDA document 07; .
Dougados M., Devogelaer J.P., Annefeldt M. (1996) Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 55:552-557.
Dougados M., LeClaire P., Van Der Heijde D. (2000) Response criteria for clinical trials on osteoarthritis of the knee and hip - A report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthritis Cartilage 8:395-403.
Thonar E.J.-M.A., Masuda K., Manicourt D.H. (1999) Structure and Function of normal human adult articular cartilage. Osteoarthrtitis clinical and experimental aspects , Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y. Eds. Springer-Verlag, New York; 1-19.
Burr D.B. (2000) Subchondral bone and osteoarthritis. Osteoarthritis Cartilage 8 SB.
Miller L.M., Hemerman D., Chance M.R., Carlson C.S. (2000) Subchondral bone in osteoarthritis. Osteoarthritis Cartilage 8 SB.
Reginster J.Y., Pelletier J.P., Martel-Pelletier J. (1999) Pathophysiology of osteoathritis. Osteoarthrtitis clinical and experimental aspects , Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y. Eds. Springer-Verlag, New York; 101-227.
Altman R.D., Hochberg M., Moskowitz R.W. (2000) Recommendations for the medical management of osteoarthritis of the hip and the knee. Arthritis Rheum 43:1905-1915.
Pendleton A., Arden N., Dougados M. (2000) EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 59:936-944.
Cashman J.N. (2000) Current pharmacotherapeutic strategies in rheumatic diseases and other pain states. Clin Drug Invest 19(S2):9-20.
Shamoon M., Hochberg M. (2000) Treatment of osteoarthritis with acetaminophen: Efficacy, safety and comparison with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2:454-458.
Dreisser R.L., Bourgeois P., De la Giclais B. (2000) Randomized double blind comparison of aleve and di-antalvic (dextropropoxyphene 30 mg and paracetamol 400 mg) for minor or moderate pain associated with osteoarthritis of the hip or knee. Osteoarthritis Cartilage 8 SB.
Eccles M., Freemantle N., Manson J. (1998) North of England evidence based guidelines development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 317:526-530.
Warner T.D., Giuliao F., Vojnovic I. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
Abramson S.R., Weissman G. (1989) The mechanisms of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum 32:1-9.
Pincus T., Griffin M. (1991) Gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs: New insights from observational studies and functional status questionnaires. Am J Med 91:209-212.
Emery P., Zeidler H., Kvien T.K. (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 354:2106-2111.
Laine L., Harper S., Simon T. (1999) A randomized trial comparing the effect of rofecoxib a cyclooxygenase 2-specific inhibitor with that of ibuprofen or the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology , Rofecoxib Osteoarthritis Endoscopy Study Group; 117:776-783.
Hawkey C., Laine L., Simon T. (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 43:370-377.
Huskisson E.C., Berry H., Gishen P. (1995) The effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J Rheum , LINK Study Group; 22:1941-1946.
Geba G.P., Weaver A.L., Schnitzer T.J. (2000) A clinical trial comparing rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis (OA): Early efficacy results. Ann Rheum Dis , POS; 59:291.